Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban for Arteriovenous Fistula Maturation in ESRD
NCT07559942Recruiting
- Sponsor
- Combined Military Hospital Lahore
- Start
- Jan 2026
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial comparing Apixaban group with Placebo group (2 arms). Primary endpoint: Arteriovenous Fistula Maturation at 6 weeks. Started Jan 2026; status: recruiting.
02
Drugs
apixaban
Beyond the preview
Go deeper on NCT07559942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07559942.